{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-151845","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2023-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.156014+00:00","generated_at":"2026-06-14T17:03:42.369943+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Alnylam shareholders re-elect four Class I directors, approve say-on-pay, ratify auditor","bullets":["Michael Bonney re-elected with 101.9M for vs 11.8M against; Yvonne Greenstreet 112.4M for vs 1.3M against.","Phillip Sharp re-elected 101.4M for vs 12.3M against; Elliott Sigal 110.1M for vs 3.6M against.","Say-on-pay approved: 109.7M for, 4.0M against; 1-year frequency recommended with 113.5M votes.","PricewaterhouseCoopers ratified as independent auditor for FY2023: 116.1M for, 1.8M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-151845","json":"https://secwatch.observer/filing/0001193125-23-151845.json","markdown":"https://secwatch.observer/filing/0001193125-23-151845.md","text":"https://secwatch.observer/filing/0001193125-23-151845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523151845/0001193125-23-151845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523151845/d689062d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T17:03:42.369943+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0367e87e6148abeaf42610535f438f80c0a74e2e","claim":"ALNYLAM PHARMACEUTICALS, INC. shareholders approved Advisory vote on named executive officer compensation at the 2023-05-18 meeting.","evidence_excerpt":"The Company’s stockholders approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523151845/0001193125-23-151845-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-18"}],"fact_type":"shareholder_vote"},{"claim_id":"9a648d045cd330c24a4052686fed653803750856","claim":"ALNYLAM PHARMACEUTICALS, INC. shareholders approved Advisory vote on frequency of future advisory votes on named executive officer compensation at the 2023-05-18 meeting.","evidence_excerpt":"The Company’s stockholders recommended, in a non-binding advisory vote, a frequency of every One Year for future advisory stockholder votes on the compensation of the Company’s named executive officers.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523151845/0001193125-23-151845-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-18"}],"fact_type":"shareholder_vote"},{"claim_id":"c2403e1012bd348d89156bffb75d25ea89f1124f","claim":"ALNYLAM PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors at the 2023-05-18 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment by the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523151845/0001193125-23-151845-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-18"}],"fact_type":"shareholder_vote"},{"claim_id":"e98458ad0b7371e573db531b0f9d3102b68166c3","claim":"ALNYLAM PHARMACEUTICALS, INC. shareholders approved Election of Class I Directors at the 2023-05-18 meeting.","evidence_excerpt":"The Company’s stockholders re-elected the four persons listed below as Class I directors, each to serve until the Company’s 2026 annual meeting of stockholders or until his or her successor is duly elected and qualified.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523151845/0001193125-23-151845-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-18"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}